Edition:
India

Knight Therapeutics Inc (GUD.TO)

GUD.TO on Toronto Stock Exchange

7.55CAD
19 Jul 2019
Change (% chg)

$0.05 (+0.67%)
Prev Close
$7.50
Open
$7.48
Day's High
$7.58
Day's Low
$7.47
Volume
280,884
Avg. Vol
376,111
52-wk High
$8.81
52-wk Low
$7.10

Latest Key Developments (Source: Significant Developments)

Knight Therapeutics Announces Health Canada Has Approved Nerlynx For Early-Stage Breast Cancer
Wednesday, 17 Jul 2019 

July 16 (Reuters) - Knight Therapeutics Inc ::KNIGHT THERAPEUTICS ANNOUNCES HEALTH CANADA HAS APPROVED NERLYNX ® FOR EARLY-STAGE BREAST CANCER.KNIGHT THERAPEUTICS INC - HAS EXCLUSIVE RIGHT TO COMMERCIALIZE NERLYNX IN CANADA UNDER A LICENSE AGREEMENT WITH PUMA BIOTECHNOLOGY.  Full Article

Medison Biotech Says Kevin Cameron, Together With New Independent Nominee Michael Tremblay, Are Elected To Knight Board
Wednesday, 8 May 2019 

May 7 (Reuters) - Knight Therapeutics Inc ::MEDISON BIOTECH SAYS ITS CAMPAIGN CREATED UNANIMOUS CONSENT THAT AN IMMEDIATE CHANGE IS REQUIRED AT KNIGHT THERAPEUTICS.MEDISON BIOTECH CEO SAYS "DECIDED TO WITHDRAW MY NOMINATION FOR THE BOARD, AS I BELIEVE I CAN BE MORE EFFECTIVE OPERATING FROM THE OUTSIDE AS AN ACTIVE SHAREHOLDER".MEDISON BIOTECH SAYS ITS NOMINEE KEVIN CAMERON, TOGETHER WITH NEW INDEPENDENT NOMINEE MICHAEL TREMBLAY, ARE ELECTED TO KNIGHT BOARD OF DIRECTORS.  Full Article

Knight Quarterly Basic Earnings Per Share $0.002
Thursday, 14 Mar 2019 

March 14 (Reuters) - Knight Therapeutics Inc ::KNIGHT REPORTS 2018 FOURTH QUARTER AND YEAR END RESULTS.KNIGHT THERAPEUTICS INC QUARTERLY BASIC EARNINGS PER SHARE $0.002.KNIGHT THERAPEUTICS INC QUARTERLY REVENUES $3.9 MILLION VERSUS $2.5 MILLION.  Full Article

Puma Biotechnology To Receive Payments Up To $7.2 Mln From License Agreement With Knight Therapeutics
Friday, 11 Jan 2019 

Jan 11 (Reuters) - Puma Biotechnology Inc::PUMA BIOTECHNOLOGY AND KNIGHT THERAPEUTICS ENTER INTO EXCLUSIVE LICENSE AGREEMENT TO COMMERCIALIZE NERLYNX® (NERATINIB) IN CANADA.PUMA BIOTECHNOLOGY INC - PUMA WILL RECEIVE UPFRONT AND MILESTONE PAYMENTS UP TO $7.2 MILLION USD THROUGHOUT TERM OF THIS AGREEMENT.PUMA BIOTECHNOLOGY INC - KNIGHT WILL BE RESPONSIBLE FOR ALL COMMERCIAL ACTIVITIES AND FUTURE REGULATORY SUBMISSIONS FOR NERLYNX IN CANADA.  Full Article

Knight Therapeutics Enters License Agreement With Puma Biotechnology To Commercialize Nerlynx In Canada
Friday, 11 Jan 2019 

Jan 11 (Reuters) - Knight Therapeutics Inc ::KNIGHT THERAPEUTICS INC - ENTERED INTO LICENSE AGREEMENT WITH PUMA BIOTECHNOLOGY GRANTING CO EXCLUSIVE RIGHT TO COMMERCIALIZE NERLYNX IN CANADA.  Full Article

Knight Therapeutics And Jaguar Health Announce Strategic Partnership
Tuesday, 25 Sep 2018 

Sept 24 (Reuters) - Knight Therapeutics Inc ::KNIGHT THERAPEUTICS AND JAGUAR HEALTH ANNOUNCE STRATEGIC PARTNERSHIP.KNIGHT THERAPEUTICS INC - TO BE RESPONSIBLE FOR ALL REGULATORY AND COMMERCIAL ACTIVITIES FOR MYTESI AND RELATED PRODUCTS IN LICENSED TERRITORIES.KNIGHT THERAPEUTICS - UPON ACHIEVEMENT OF REGULATORY, SALES MILESTONES IN AGREEMENT, JAGUAR TO RECEIVE PAYMENTS FROM CO OF UP TO $18.0 MILLION.KNIGHT THERAPEUTICS - AGREEMENT GRANTS CO EXCLUSIVE RIGHT TO COMMERCIALIZE MYTESI AND RELATED PRODUCTS IN CANADA AND ISRAEL.KNIGHT THERAPEUTICS INC - AGREEMENT GRANTS CO A RIGHT OF FIRST NEGOTIATION TO COMMERCIALIZE MYTESI & RELATED PRODUCTS IN SPECIFIED LATAM COUNTRIES.KNIGHT THERAPEUTICS INC - JAGUAR IS ALSO PURSUING POSSIBLE FOLLOW-ON INDICATIONS FOR MYTESI IN CANCER THERAPY-RELATED DIARRHEA.KNIGHT THERAPEUTICS - JAGUAR TO RECEIVE PAYMENTS FROM CO OF UP TO $18.0 MILLION THROUGHOUT INITIAL 15-YEAR TERM OF AGREEMENT.  Full Article

Knight Therapeutics Reports Q2 Basic EPS $0.028
Thursday, 9 Aug 2018 

Aug 9 (Reuters) - Knight Therapeutics Inc ::KNIGHT THERAPEUTICS REPORTS SECOND QUARTER 2018 RESULTS.QTRLY BASIC EARNINGS PER SHARE $ 0.028.QTRLY REVENUES $2.2 MILLION, DOWN 10 PERCENT.  Full Article

Knight Therapeutics And TherapeuticsMD Announce Strategic Partnership
Wednesday, 1 Aug 2018 

July 31 (Reuters) - Knight Therapeutics Inc ::KNIGHT THERAPEUTICS AND THERAPEUTICSMD ANNOUNCE STRATEGIC PARTNERSHIP.KNIGHT THERAPEUTICS - CO, THERAPEUTICSMD ENTERED LICENSING AGREEMENT THAT GRANTS CO RIGHTS TO COMMERCIALIZE TX-004HR AND TX-001HR IN CANADA AND ISRAEL.KNIGHT THERAPEUTICS INC - WILL PAY THERAPEUTICSMD A MILESTONE FEE UPON FIRST REGULATORY APPROVAL IN CANADA OF EACH OF TX-004HR AND TX-001HR.KNIGHT THERAPEUTICS - AGREED TO INVEST $20 MILLION IN THERAPEUTICSMD COMMON STOCK ALONG WITH CLOSING OF PUBLIC OFFERING OF THERAPEUTICSMD COMMON STOCK.  Full Article

KNIGHT THERAPEUTICS REPORTS Q3 EARNINGS PER SHARE $0.03
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Knight Therapeutics Inc :KNIGHT REPORTS THIRD QUARTER 2017 RESULTS.QTRLY ‍REVENUE $1.9 MILLION, A DECREASE OF 2 PERCENT​.QTRLY EARNINGS PER SHARE $0.03‍​.‍ALL CURRENCIES ARE CANADIAN​.  Full Article

Knight Therapeutics reports qtrly earnings per share $0.03‍​
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Knight Therapeutics Inc ::Knight reports third quarter 2017 results.Qtrly earnings per share $0.03.Q3 earnings per share view C$0.03 -- Thomson Reuters I/B/E/S‍​.Qtrly ‍revenues were $1.9 million, a decrease of 2 percent versus same period in prior year​.All currencies are Canadian‍​.  Full Article